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OBJECTIVES: Pharmacotherapy costs represents huge burden
for health institutions. The aim of the study is to compare pre-
scribing practice and cost of outpatient hypertension pharmaco-
therapy between Bulgaria and Serbia. METHODS: A one year
retrospective study from the point of view of the health system
was performed, based on the collected reimbursed prescriptions
with diagnosis AH (I10–I11) and for its complications—heart
failure (I.50); sequelae of cerebrovascular disease (I.69); angina
pectoris (I.20). Therapy was analysed according to the complex-
ity (mono-, di-, etc.), frequency of prescribed medicines, reim-
bursed drug prices, and patient co-payment. To calculate the cost
of the outpatient therapy was build a decision tree model match-
ing the frequency of particular brand name prescribing, their
prices, and complexity of therapy. RESULTS: The relative share
of uncomplicated hypertension is comparable (67% in Serbia
and 65% in Bulgaria). The ACE inhibitors are the ﬁrst choice for
hypertension treatment in both countries. Hypertension mono-
therapy differs signiﬁcantly (47% in Bulgaria and 6% in Serbia),
while di-therapy is comparable (35% and 30%). Among the
complications prevails prescriptions for angine pectoris (70% in
Serbia and 42% in Bulgaria) and heart failure (7% and 26%).
The complications are usually treated with more than one medi-
cine in Serbia while the monotherapy in Bulgaria is 66%. By
including the cost and prevalence of mono-, di- etc therapy in the
“decision tree” model we receive that the waged monthly cost of
outpatient pharmacotherapy per patient with uncomplicated
hypertension account for €12.56 in Serbia and €6.90 in Bulgaria.
The total monthly cost of hypertension considering the chance of
having complications is €13.39 in Serbia and €8.23 in Bulgaria.
Patient co-payment in Bulgaria is higher. CONCLUSIONS: Inter-
national cost comparisons are possible but depend on many
external factors as regulatory and price control measures, pre-
scribing habits, reimbursement policy.
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COST-EFFECTIVENESS OF GADOFOSVESET-ENHANCED
MAGNETIC RESONANCE (MR) ANGIOGRAPHY FORTHE
PATIENTS WITH CHRONIC PERIPHERAL ARTERIAL
OBSTRUCTIVE DISEASE (PAOD) IN KOREA
Choi SE, Choi YG, Lim EA
Seoul National University, Seoul, South Korea
OBJECTIVES: To assess the cost-effectiveness of gadofosveset-
enhanced MR Angiography (VV-MRA) compared with conven-
tional extracellular contrast agents enhanced MRA (EC-MRA),
and computed-tomography angiography (CTA) for the diagnosis
and treatment of chronic PAOD patients in Korea. METHODS:
It is assumed that diagnostic test affects the treatment decision
and the patient’s health outcome consequently. Decision analytic
model based on the published clinical guidelines for the PAOD
diagnosis and treatment was constructed. We adopted societal
perspective and 1 year time horizon. The sensitivity and speci-
ﬁcity of imaging diagnostic tests were extracted from published
studies to estimate probabilities of diagnostic positive and posi-
tive predictability. The studies that used the conventional angiog-
raphy or digital subtraction angiography as a gold standard were
included. Costs broke down into imaging costs and treatment
costs. They were collected from experts’ panel survey and
National Health Insurance Claims database. All costs were
expressed in 2007. Quality weights for health outcomes were
extracted from published studies. Incremental cost-effectiveness
ratio was calculated and sensitivity analysis for various uncertain
parameters was conducted. RESULTS: For the base case analysis,
incremental cost per QALY of VV-MRA was 24,591,939KRW/
QALY (US426,078/QALY) compared with CTA, and EC-MRA
was dominated. The results of sensitivity analysis showed that
the costs of imaging and treatments, and the probabilities of the
treatment options didn’t change the results. The result could be
inﬂuenced by prevalence rate. CONCLUSIONS: VV-MRA tech-
nique was the cost-effective option compared with EC-MRA and
CTA for diagnosis for patients with chronic peripheral arterial
obstructive disease.
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OBJECTIVES: Stroke is the second leading cause of death in
China, and its incidence is expected to increase over the years
despite primary prevention efforts. The aim of this study was to
compare the costs and health effects of stroke rehabilitation
strategies in eastern China. METHODS: A literature review of
the possible stroke rehabilitation strategies was conducted to
compare their impact on costs and health effects. Treatment
effects were based on changes measured using functionality
scales such as the Modiﬁed Barthel Index (MBI). These changes
were transformed into general health-related quality of life
(QOL) improvement according to a generic QOL instrument
(EQ-5D). Costs included direct medical and non-medical costs
but did not include indirect costs. RESULTS: Three different
strategies could be identiﬁed. The ﬁrst strategy is one month of
hospitalization including rehabilitation, which is what most
stroke patients receive. The second is one month of hospitaliza-
tion with rehabilitation for six months. The third strategy is
hospitalization for six months and no active rehabilitation.
Rehabilitation for six months achieves the greatest health
improvement (MBI = 65) but at the greatest cost (RMB34,000),
while one month of hospital including rehabilitation is the least
effective (MBI = 35) and cheapest strategy (RMB19,000 RMB).
Extended hospitalization without rehabilitation results in inter-
mediate costs and effects (MBI = 45 at a cost of RMB29,500).
CONCLUSIONS: Full rehabilitation for six months appears to
be the most cost effective option for stroke patients in China.
Unfortunately, this strategy is out of reach for most Chinese
patients, and this is due to many factors including lack of facili-
ties and skilled personnel. Efforts need to be taken to ﬁnd effec-
tive and cost-effective strategies that can be provided to the
majority of Chinese stroke patients.
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COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF
TRITACE COMB (RAMIPRIL/HCTZ) INTREATMENT OF
HYPERTENSION IN POLAND
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OBJECTIVES: To determine the cost-effectiveness and cost-
utility of Tritace Comb (ramipril+ hydrochlorothiazide) com-
pared to standard therapy of ramipril and hydrochlorothiazide
(HCTZ) used in monotherapy and compared to compound
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